No Data
No Data
KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $4
KeyBanc Cuts Price Target on AbCellera Biologics to $4 From $5, Keeps Overweight Rating
Is AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts?
Insiders Of AbCellera Biologics Are Up 20% On Their US$740.0k Purchase
Is AbCellera Biologics (NASDAQ:ABCL) In A Good Position To Invest In Growth?
Express News | Watching AbCellera Biologics; Shares See Volume To The Upside, Traders Circulate Ray Blancos Catalyst Trader Action Alert To Buy The Stock Up To $4